Kelly WK - Search Results

1

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. Halabi S, et al. Among authors: kelly wk. J Clin Oncol. 2014 Mar 1;32(7):671-7. doi: 10.1200/JCO.2013.52.3696. Epub 2014 Jan 21. J Clin Oncol. 2014. PMID: 24449231 Free PMC article.

2

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Ghossein RA, et al. Among authors: kelly wk. J Clin Oncol. 1995 May;13(5):1195-200. doi: 10.1200/JCO.1995.13.5.1195. J Clin Oncol. 1995. PMID: 7537803

3

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2208-13. doi: 10.1200/JCO.1995.13.9.2208. J Clin Oncol. 1995. PMID: 7545218 Clinical Trial.

4

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2214-22. doi: 10.1200/JCO.1995.13.9.2214. J Clin Oncol. 1995. PMID: 7666079 Clinical Trial.

5

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Kelly WK, et al. J Clin Oncol. 1993 Apr;11(4):607-15. doi: 10.1200/JCO.1993.11.4.607. J Clin Oncol. 1993. PMID: 7683043

6

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Scher HI, Kelly WK. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 1993 Aug;11(8):1566-72. doi: 10.1200/JCO.1993.11.8.1566. J Clin Oncol. 1993. PMID: 7687666

7

Acid phosphatase: defining a role in androgen-independent prostate cancer.

Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI. Steineck G, et al. Among authors: kelly wk. Urology. 1996 May;47(5):719-26. doi: 10.1016/s0090-4295(96)00017-9. Urology. 1996. PMID: 8650872

8

Clinical trials in relapsed prostate cancer: defining the target.

Scher HI, Mazumdar M, Kelly WK. Scher HI, et al. Among authors: kelly wk. J Natl Cancer Inst. 1996 Nov 20;88(22):1623-34. doi: 10.1093/jnci/88.22.1623. J Natl Cancer Inst. 1996. PMID: 8931606 Review.

9

Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer.

Kelly WK, Slovin S, Scher HI. Kelly WK, et al. Semin Oncol. 1996 Dec;23(6 Suppl 14):8-14. Semin Oncol. 1996. PMID: 8996578 Review.

10

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.

Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI. Slovin SF, et al. Among authors: kelly wk. Semin Oncol. 1996 Dec;23(6 Suppl 14):41-8. Semin Oncol. 1996. PMID: 8996585 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters